Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis
- 1 May 2013
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Gastroenterology & Hepatology
- Vol. 25 (5), 523-530
- https://doi.org/10.1097/meg.0b013e32835d09fe
Abstract
Refractory ascites and recurrent variceal bleeding are among the serious complications of portal hypertension and cirrhosis for which a transjugular intrahepatic portosystemic shunt (TIPS) can be used. Cirrhotic patients have varying degrees of haemodynamic derangement, mainly characterized by peripheral arterial vasodilatation, central underfilling and activation of several vasoactive systems. These changes affect the heart, the lungs and the kidneys in particular. The cardiac effects of TIPS are immediate and are related to the redirection of blood from the splanchnic circulation into the systemic circulation, resulting in worsening of the hyperdynamic circulation with increasing cardiac output and decreasing systemic vascular resistance; further, TIPS may unmask a latent diastolic dysfunction of the heart. However, the renal effects of TIPS seem to be beneficial as renal function tends to improve in patients with the hepatorenal syndrome. The clinical and haemodynamic effects of TIPS have been studied intensively and will be reviewed in the present paper. Considerable knowledge on the effects of TIPS on the pathophysiology of cirrhosis has been gained, but studies on the central haemodynamic effects are warranted to refine the already applied treatments and develop new treatment modalities.Keywords
This publication has 42 references indexed in Scilit:
- Cirrhotic cardiomyopathyJournal of Hepatology, 2010
- TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical updateGut, 2010
- Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascitesGut, 2009
- The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009Hepatology, 2009
- Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndromeJournal of Hepatology, 2007
- Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndromeHepatology, 2004
- Renal failure in cirrhotic patientsEuropean Journal of Gastroenterology & Hepatology, 2002
- Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II studyGut, 2000
- Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systemsHepatology, 1998
- Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosisJournal of Hepatology, 1991